JPRN-UMIN000005984招募中未知
Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer. - Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.
Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)0 个研究点目标入组 20 人开始时间: 2011年7月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity to DCS. 2) Contraindication to Docetaxel, CDDP, S-1, G-CSF. 3) Infectious disease. 4) Severe complication. 5) Neuropathy greater than grade 2. 6) Watery diarrhea. 7) Active double cancer. 8) Persons to be pregnant or to make pregnant.
研究者
相似试验
未知
2 期
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
已完成
不适用
A feasibility study of docetaxel + cisplatin + capecitabine (DCX) therapy for unresectable advanced gastric cancerGastric cancerJPRN-UMIN000006009Department of Gastroenterology, Nagoya University Graduate School of Medicine6
已完成
2 期
Efficacy and feasibility study of docetaxel + capecitabine followed by FEC neoadjuvant therapy for hormone receptor positive and HER2 negative breast cancerBreast cancerJPRN-UMIN000013274Department of Surgical Oncology, Osaka City University Graduate School of Medicine20
已完成
2 期
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601)Gastric cancerJPRN-UMIN000001119Department of Gastroenterology, Kitasato University School of Medicine45
招募中
不适用
Phase I/II study of bi-weekly docetaxel and cisplatin plus S-1 (bi-weekly DCS) as first-line therapy for advanced esophageal cancer.Esophageal cancerJPRN-UMIN000032257The University of Tokyo50